Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B streptococcal disease

被引:106
作者
Mancuso, G
Midiri, A
Beninati, C
Biondo, C
Galbo, R
Akira, S
Henneke, P
Golenbock, D
Teti, G
机构
[1] Univ Messina, Sch Med, Dept Pathol & Expt Microbiol, Messina, Italy
[2] Osaka Univ, Microbial Dis Res Inst, Osaka, Japan
[3] Univ Massachusetts, Dept Med, Div Infect Dis & Immunol, Sch Med, Worcester, MA 01605 USA
[4] Univ Freiburg, Childrens Hosp, Freiburg, Germany
关键词
D O I
10.4049/jimmunol.172.10.6324
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Toll-like receptors (TLRs) are involved in pathogen recognition by the innate immune system. Different TLRs and the adaptor molecule myeloid differentiation factor 88 (MyD88) were previously shown to mediate in vitro cell activation induced by group B streptococcus (GBS). The present study examined the potential in vivo roles of TLR2 and MyD88 during infection with GBS. When pups were infected locally with a low bacterial dose, none of the TLR2- or MyD88-deficient mice, but all of the wild-type ones, were able to prevent systemic spread of GBS from the initial focus. Bacterial burden was higher in MyD88- than in TLR2-deficient mice, indicating a more profound defect of host defense in the former animals. In contrast, a high bacterial dose induced high level bacteremia in both mutant and wild-type mice. Under these conditions, however, TLR2 or MyD88 deficiency significantly protected mice from lethality, concomitantly with decreased circulating levels of TNF-alpha and IL-6. Administration of anti-TNF-alpha Abs to wild-type mice could mimic the effects of TLR2 or MyD88 deficiency and was detrimental in the low dose model, but protective in the high dose model. In conclusion, these data highlight a dual role of TLR2 and MyD88 in the host defense against GBS sepsis and strongly suggest TNF-alpha as the molecular mediator of bacterial clearance and septic shock.
引用
收藏
页码:6324 / 6329
页数:6
相关论文
共 33 条
[1]   Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function [J].
Adachi, O ;
Kawai, T ;
Takeda, K ;
Matsumoto, M ;
Tsutsui, H ;
Sakagami, M ;
Nakanishi, K ;
Akira, S .
IMMUNITY, 1998, 9 (01) :143-150
[2]   Early-onset neonatal sepsis in the era of group B streptococcal prevention [J].
Baltimore, RS ;
Huie, SM ;
Meek, JI ;
Schuchat, A ;
O'Brien, KL .
PEDIATRICS, 2001, 108 (05) :1094-1098
[3]   Plasma levels and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor-α, interleukin (IL)-1β, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis [J].
Berner, R ;
Niemeyer, CM ;
Leititis, JU ;
Funke, A ;
Schwab, C ;
Rau, U ;
Richter, K ;
Tawfeek, MSK ;
Clad, A ;
Brandis, M .
PEDIATRIC RESEARCH, 1998, 44 (04) :469-477
[4]   Predisposing conditions and pathogens in bacteremia in hospitalized children [J].
Berner, R ;
Schumacher, RF ;
Bartelt, S ;
Forster, J ;
Brandis, M .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (05) :337-340
[5]   Neonatal hypersusceptibility to endotoxin correlates with increased tumor necrosis factor production in mice [J].
Cusumano, V ;
Mancuso, G ;
Genovese, F ;
Cuzzola, M ;
Carbone, M ;
Cook, JA ;
Cochran, JB ;
Teti, G .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (01) :168-176
[6]   MyD88-dependent but Toll-like receptor 2-independent innate immunity to Listeria:: No role for either in macrophage listericidal activity [J].
Edelson, BT ;
Unanue, ER .
JOURNAL OF IMMUNOLOGY, 2002, 169 (07) :3869-3875
[7]   Risk and the efficacy of antiinflammatory agents - Retrospective and confirmatory studies of sepsis [J].
Eichacker, PQ ;
Parent, C ;
Kalil, A ;
Esposito, C ;
Cui, X ;
Banks, SM ;
Gerstenberger, EP ;
Fitz, Y ;
Danner, RL ;
Natanson, C .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (09) :1197-1205
[8]   The role of lipopolysaccharide binding protein in resistance to Salmonella infections in mice [J].
Fierer, J ;
Swancutt, MA ;
Heumann, D ;
Golenbock, D .
JOURNAL OF IMMUNOLOGY, 2002, 168 (12) :6396-6403
[9]   ANTIBODIES TO TUMOR-NECROSIS-FACTOR-ALPHA - USE AS ADJUNCTIVE THERAPY IN ESTABLISHED GROUP-B STREPTOCOCCAL DISEASE IN NEWBORN RATS [J].
GIVNER, LB ;
GRAY, L ;
OSHEA, TM .
PEDIATRIC RESEARCH, 1995, 38 (04) :551-554
[10]  
Gotoff Samuel P, 2002, Pediatr Rev, V23, P381